查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019303

全球凝血酶原複合物濃縮物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Prothrombin Complex Concentrate Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 138 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

凝血酶原複合物濃縮液(PCC) 市場預計將從 2025 年的 30.5 億美元成長到 2034 年的 70.7 億美元，預計從 2026 年到 2034 年將以 9.79% 的複合年成長率成長。

由於出血性疾病發生率上升以及在緊急情況下逆轉抗凝血治療的應用日益廣泛，全球凝血酶原複合物濃縮物 (PCC) 市場正經歷穩定成長。與傳統血漿療法相比，PCC 起效更快，因此醫院和創傷中心擴大採用 PCC 產品。外科手術和創傷病例的增加進一步推動了市場需求，尤其是在醫療體系發達、能夠便捷地獲得先進治療方法的國家。

主要促進因素包括抗凝血治療的廣泛應用，尤其是在心血管疾病領域，這導致了對凝血酶原複合物濃縮物（PCC）等逆轉劑的相應需求。此外，血漿分餾技術的進步和安全性的提高也加速了產品的普及。同時，一些地區的政府支持和優惠的報銷政策也促進了這些濃縮製劑在臨床實踐中的更廣泛應用。

隨著配方改進和臨床應用範圍拓展的研究不斷深入，市場預計將持續成長。在新興市場，隨著醫療基礎設施的改善，可能會出現顯著的成長機會。此外，隨著醫療專業人員對快速止血管理的認知不斷提高，預計需求將進一步成長，凝血酶原複合物濃縮物（PCC）有望成為全球急診醫學的關鍵組成部分。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球凝血酶原複合物濃縮物市場：依產品類型分類

  • 市場分析、洞察與預測
  • 四因素PCC
  • 三因素PCC

第5章：全球凝血酶原複合物濃縮物市場：依應用分類

  • 市場分析、洞察與預測
  • 後天性凝血因子缺乏症
  • 先天性凝血因子缺乏症
  • 其他用途

第6章：全球凝血酶原複合物濃縮物市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院
  • 門診手術中心
  • 其他最終用戶

第7章 全球凝血酶原複合物濃縮物市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • CSL
    • Baxter
    • Emergent BioSolutions
    • Grifols Biologicals
    • Intas Pharmaceuticals
    • Kedrion Biopharma
    • LFB Group
    • Octapharma
    • Pfizer
    • Prothya Biosolutions
    • Takeda Pharmaceuticals
簡介目錄
Product Code: VMR11214580

The Prothrombin Complex Concentrate Market size is expected to reach USD 7.07 Billion in 2034 from USD 3.05 Billion (2025) growing at a CAGR of 9.79% during 2026-2034.

The global prothrombin complex concentrate (PCC) market has been witnessing steady growth due to the rising prevalence of bleeding disorders and increasing use in emergency anticoagulation reversal. Hospitals and trauma centers are increasingly adopting PCC products because of their rapid action compared to traditional plasma therapies. The growing number of surgeries and trauma cases has further contributed to demand, especially in developed healthcare systems where advanced treatment options are readily available.

Key drivers include the increasing use of anticoagulant therapies, particularly for cardiovascular diseases, which creates a parallel demand for reversal agents like PCC. Additionally, advancements in plasma fractionation technologies and improved safety profiles have enhanced product adoption. Government support and favorable reimbursement policies in several regions are also encouraging wider use of these concentrates in clinical practice.

Looking ahead, the market is expected to expand with ongoing research into improved formulations and broader clinical applications. Emerging markets are likely to offer significant growth opportunities due to improving healthcare infrastructure. Furthermore, increasing awareness among healthcare professionals regarding rapid bleeding management is expected to boost demand, positioning PCC as a critical component in emergency medicine globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

  • 4-Factor PCC
  • 3-Factor PCC

By Application

  • Acquired Coagulation Factor Deficiency
  • Congenital Coagulation Factor Deficiency
  • Other Applications

By End Use

  • Hospitals
  • Ambulatory Surgical Centers
  • Other End Users

COMPANIES PROFILED

  • CSL, Baxter, Emergent BioSolutions, Grifols Biologicals, Intas Pharmaceuticals, Kedrion Biopharma, LFB Group, Octapharma, Pfizer, Prothya Biosolutions, Takeda Pharmaceuticals
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product Type
  • 4.2. 4-Factor PCC Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. 3-Factor PCC Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Acquired Coagulation Factor Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Congenital Coagulation Factor Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET: BY END USE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End Use
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Product Type
    • 7.2.2 By Application
    • 7.2.3 By End Use
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Product Type
    • 7.3.2 By Application
    • 7.3.3 By End Use
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Product Type
    • 7.4.2 By Application
    • 7.4.3 By End Use
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Product Type
    • 7.5.2 By Application
    • 7.5.3 By End Use
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Product Type
    • 7.6.2 By Application
    • 7.6.3 By End Use
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROTHROMBIN COMPLEX CONCENTRATE INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 CSL
    • 9.2.2 Baxter
    • 9.2.3 Emergent BioSolutions
    • 9.2.4 Grifols Biologicals
    • 9.2.5 Intas Pharmaceuticals
    • 9.2.6 Kedrion Biopharma
    • 9.2.7 LFB Group
    • 9.2.8 Octapharma
    • 9.2.9 Pfizer
    • 9.2.10 Prothya Biosolutions
    • 9.2.11 Takeda Pharmaceuticals